GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akebia Therapeutics Inc (STU:AX9) » Definitions » Cyclically Adjusted FCF per Share

Akebia Therapeutics (STU:AX9) Cyclically Adjusted FCF per Share : €-0.92 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was €-0.052. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.92 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-06-25), Akebia Therapeutics's current stock price is €3.138. Akebia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €-0.92. Akebia Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Akebia Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Akebia Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Cyclically Adjusted FCF per Share Chart

Akebia Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1.23 -1.40 -1.01

Akebia Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.07 -1.04 -0.98 -1.01 -0.92

Competitive Comparison of Akebia Therapeutics's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Akebia Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.052/134.9266*134.9266
=-0.052

Current CPI (Mar. 2025) = 134.9266.

Akebia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.407 100.684 -0.545
201509 -0.283 100.392 -0.380
201512 -0.695 99.792 -0.940
201603 0.422 100.470 0.567
201606 -0.664 101.688 -0.881
201609 -0.694 101.861 -0.919
201612 2.368 101.863 3.137
201703 -0.240 102.862 -0.315
201706 0.528 103.349 0.689
201709 -0.987 104.136 -1.279
201712 -0.300 104.011 -0.389
201803 -0.344 105.290 -0.441
201806 0.133 106.317 0.169
201809 -0.192 106.507 -0.243
201812 -0.942 105.998 -1.199
201903 -1.057 107.251 -1.330
201906 -0.302 108.070 -0.377
201909 0.065 108.329 0.081
201912 -0.696 108.420 -0.866
202003 -0.631 108.902 -0.782
202006 0.241 108.767 0.299
202009 -0.161 109.815 -0.198
202012 -0.174 109.897 -0.214
202103 -0.387 111.754 -0.467
202106 -0.325 114.631 -0.383
202109 -0.275 115.734 -0.321
202112 -0.318 117.630 -0.365
202203 -0.110 121.301 -0.122
202206 -0.152 125.017 -0.164
202209 0.186 125.227 0.200
202212 -0.281 125.222 -0.303
202303 -0.089 127.348 -0.094
202306 0.018 128.729 0.019
202309 -0.036 129.860 -0.037
202312 -0.011 129.419 -0.011
202403 -0.087 131.776 -0.089
202406 -0.045 132.554 -0.046
202409 -0.029 133.029 -0.029
202412 -0.019 133.157 -0.019
202503 -0.052 134.927 -0.052

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Akebia Therapeutics  (STU:AX9) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Akebia Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics Business Description

Traded in Other Exchanges
Address
245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Headlines

No Headlines